Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma.

The company was founded in 2005 and is headquartered in Bridgewater, New Jersey with research facilities in Research Triangle Park, North Carolina.

Aerie Pharmaceuticals, Inc. is a former subsidiary of Duke University Medical Center.

Type
Public
HQ
Irvine, US
Founded
2005
Employees
70 (est)
Aerie Pharmaceuticals was founded in 2005 and is headquartered in Irvine, US

Key People at Aerie Pharmaceuticals

Gerald D. Cagle

Gerald D. Cagle

COO, Cognoptix Inc.; Former SVP, Research & Development; CSO, Alcon Laboratories Inc.
Casey C. Kopczynski

Casey C. Kopczynski

Chief Research Officer and Co-Founder
Thomas A. Mitro

Thomas A. Mitro

President and Chief Operating Officer
Richard J. Rubino

Richard J. Rubino

Chief Financial Officer
Dennis Henner

Dennis Henner

Managing Director Clarus Ventures
Murray Goldberg

Murray Goldberg

Chief Financial Officer Regeneron Pharmaceuticals, Inc.

Aerie Pharmaceuticals Locations

Irvine, US
Bedminster Township, US

Aerie Pharmaceuticals Metrics

Aerie Pharmaceuticals Summary

Market capitalization

$1.35 B

Closing share price

$38.5
Aerie Pharmaceuticals's latest market capitalization is $1.35 B.

Aerie Pharmaceuticals Market Value History

23% of current employees of Aerie Pharmaceuticals are female and 77% are male.

Aerie Pharmaceuticals News

Aerie Pharmaceuticals Company Life

You may also be interested in